Search Results for "En Vivo EVP6124 Alzheimer"

17:10 EDT 1st July 2015 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Amyloid Formation May Link Alzheimer, Type 2 Diabetes

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D...

In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA

Amyloid Formation May Link Alzheimer's, Type 2 Diabetes

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D...

Transition Therapeutics Aims to Amplify the Alzheimer’s Conversation Through Mediaplanet’s “Fighting Alzheimer’s” Campaign

New York, NY (PRWEB) June 19, 2015 With Alzheimer’s being the nation’s sixth-leading cause of death and with no cure and a rapidly increasing number of people suffering, the dedicated com...

Does Amyloid Kill in Alzheimer’s, Heal in MS?

Two groups have recently made strides with amyloid beta (aβ), the supposed main villain in Alzheimer’s disease. But while one group is tackling Alzheimer’s by reducing aβ, the other is tackling ...

Vivo closes eighth fund with $750M

Vivo Capital said it closed Vivo Capital Fund VIII with $750 million. Vivo intends to invest the fund in late-stage pharma and medical device companies in the U.S. and in revenue-stage healthcare comp...

Carefusion Signs Exclusive Ventilator Distribution Agreement with Breas

CareFusion, a San Diego-based medical technology company, announced it has signed an exclusive distribution agreement for the U.S. with Breas Medical for their Vivo line of ventilation equipment. U...

Forgetfulness and Errors Can Signal Alzheimer’s Decades Before Diagnosis

Mistakes on memory and thought tests may give an indication of the future onset of Alzheimer’s, up to 18 years before diagnosis, according to a new study. More than 2,000 people from Chicago withou...

Matching PubMed Articles

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density.

In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease.

Prevention of Alzheimer disease The roles of nutrition and primary care.

Risk factors for developing Alzheimer disease include hypercholesterolemia, hypertension, obesity, and diabetes. Due to lack of effective treatments for Alzheimer disease (AD), primary prevention beco...

Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A "Real-Life" Study.

There is little knowledge of the long-term course of Alzheimer disease (AD) in light of current pharmacological and nonpharmacological interventions provided in a "real-life" setting.

The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs.

The incidence and prevalence of global dementia and AlzheimerâÄôs disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in ...

Outpatient treatment of sleep disorders in Alzheimer patients.

Sleep disorders are common in patients with Alzheimer dementia and affect the quality of life of patients and of their caregivers. Despite the rising number of studies in the area, almost all of them ...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement